

Preliminary Amendment

Serial No.: 09/640,935

Filed: 17 August 2000

For: EPHA2 AS A THERAPEUTIC TARGET FOR METASTATIC CANCER (As Amended)

Page 6 of 9

A4
cont
comparing the binding of an EphA2 antibody as a function of cell density in noncancerous cells to the binding of the EphA2 antibody as a function of cell density in analogous metastatic cancer cells;

wherein an observed decrease in antibody binding to noncancerous cells as cell density increases, coupled with an observed constant level of antibody binding to the metastatic cancer cells as cell density increases, is indicative of an EphA2 antibody selective for EphA2 in metastatic cancer cells.

In the Specification

Please amend the specification as follows:

A1
At page 1, line 1, delete the title "TREATMENT OF METASTATIC DISEASE" and substitute therefor EPHA2 AS A THERAPEUTIC TARGET FOR METASTATIC CANCER.

At page 1, line 8, insert --

Government Funding

A2-
The present invention was made with government support under Grant No. DAMD 17-98-1-8146, awarded by Army Breast Cancer. The Government has certain rights in this invention.--

/
At page 1, lines 9-10, delete "an extracellular epitope of".

/
At page 5, line 7, delete "cites" and insert therefor --sites--.

/
At page 6, line 26, delete "cites" and insert therefor --sites--; and at line 31, insert a period after "malignancies".

/
At page 7, line 20, delete "analogies" and insert therefor --analogues--